Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile, PA Young… - Lung Cancer, 2018 - Elsevier
Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …
被引用次数：45 相关文章
[HTML] nih.gov

[HTML][HTML] Randomized Phase II Study of Fulvestrant and Erlotinib Compared With Erlotinib Alone in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

EB Garon, JM Siegfried, LP Stabile… - Lung cancer …, 2018 - ncbi.nlm.nih.gov
Objectives: This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

EB Garon, JM Siegfried… - Lung cancer …, 2018 - digitalcommons.providence.org
OBJECTIVES: This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.

EB Garon, JM Siegfried, LP Stabile… - Lung Cancer …, 2018 - europepmc.org
Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile, PA Young… - Lung Cancer, 2018 - hero.epa.gov
OBJECTIVES: This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile… - Lung …, 2018 - providence.elsevierpure.com
Objectives: This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile, PA Young… - Lung …, 2018 - lungcancerjournal.info
Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile… - Lung cancer …, 2018 - pubmed.ncbi.nlm.nih.gov
Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile, PA Young… - 2018 - escholarship.org
ObjectivesThis open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer

EB Garon, JM Siegfried, LP Stabile, PA Young… - Lung …, 2018 - experts.umn.edu
Objectives: This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …